Takeda boosts profit margins with AI-driven growth, FY2024 guidance upgrade, share buyback plan & promising drug launches.

Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...

Recently, the National Medical Products Administration (NMPA) issued the draft version of 'Implementation Measures for Drug Trial Data ...

Alembic Pharmaceuticals (Alembic) announced that it has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Pantoprazole Sodium.

Relacorilant, a cortisol modulator from Corcept Therapeutics Inc., produced new and strong phase III results in treating ...

As of December 31, 2024, Fortress' consolidated cash and cash equivalents totaled $57.3 million, compared to $58.9 million as ...

President Bola Tinubu has approved an extension of tenure of office for Mrs. Kemi Nanna Nandap as the Comptroller-general of ...

Vanda Pharmaceuticals (VNDA) announced that a New Drug Application was submitted to the U.S. FDA requesting marketing approval of Bysanti for ...

(Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced in addition to developing TH104 for the proposed ...

Assembly polls in the state are due later this year and the National Democratic Alliance (NDA) government led by JD(U)’s ...

Pharmaceutical Administration Bureau has approved IASO Biotherapeutics’ new drug application (NDA) for equecabtagene ...